Prevention in Atrial Fibrillation Cost-Effectiveness of Apixaban , Dabigatran , Rivaroxaban , and Warfarin for Stroke

Prevention in Atrial Fibrillation Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Print ISSN: 0039-2499. Online ISSN: 1524-4628 Copyright © 2013 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Stroke doi: 10.1161/STROKEAHA.111.000402 2013;44:1676-1681; originally published online April 2, 2013; Stroke. http://stroke.ahajournals.org/content/44/6/1676 World Wide Web at: The online version of this article, along with updated information and services, is located on the http://stroke.ahajournals.org/content/suppl/2013/04/02/STROKEAHA.111.000402.DC1.html Data Supplement (unedited) at:

[1]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[2]  A. Fendrick,et al.  Cost-utility of aspirin and proton pump inhibitors for primary prevention. , 2011, Archives of internal medicine.

[3]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine , 1997 .

[4]  R. P. Zhu,et al.  Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation , 2011, Annals of Internal Medicine.

[5]  V. Lee,et al.  Cost‐Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation—A Real Patient Data Analysis in a Hong Kong Teaching Hospital , 2013, Clinical cardiology.

[6]  D. Jonas,et al.  Patient Time Requirements for Anticoagulation Therapy with Warfarin , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  W. O'Fallon,et al.  Utilization of acute care services in the year before and after first stroke: A population-based study. , 1996, Neurology.

[8]  B. Gage,et al.  The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life , 1996 .

[9]  Vahram Ghushchyan,et al.  A National Catalog of Preference-Based Scores for Chronic Conditions in the United States , 2005, Medical care.

[10]  Tammy O. Tengs,et al.  A Meta-Analysis of Quality-of-Life Estimates for Stroke , 2012, PharmacoEconomics.

[11]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[12]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[13]  H. Kamel,et al.  Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack , 2012, Stroke.

[14]  Patrick W. Sullivan,et al.  Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[16]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .